Regeneron Says FDA Approves Eylea Injection for All Diabetic Retinopathy Treatment
May 13 2019 - 3:29PM
Dow Jones News
By Michael Dabaie
Regeneron Pharmaceuticals Inc. (REGN) said the Food and Drug
Administration approved Eylea injection to treat all stages of
diabetic retinopathy.
The company said Eylea improves diabetic retinopathy and
prevents worsening disease that can lead to blindness. Diabetic
retinopathy is the leading cause of blindness among working-aged
American adults, Regeneron said.
The FDA approval of Eylea as a treatment for diabetic
retinopathy was based on six-month and one-year results from
Panorama, a randomized, multi-center, controlled Phase 3 trial that
enrolled 402 patients.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 13, 2019 15:14 ET (19:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
